-
CSR Summary Not Yet Available
-
NCT02874742
-
Primary Citation
-
Data Specification Not Yet Available
You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NameDaratumumabProduct NameDARZALEX®Therapeutic AreaCancers and Other NeoplasmsEnrollment224% Female43.5%% White77.1%
Product ClassMonoclonal AntibodySponsor Protocol Number54767414MMY2004Data PartnerJohnson & JohnsonCondition StudiedMultiple MyelomaMean/Median Age (Years)58.2